| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 00703-5656-01 | 00703-5656 | Etoposide | Toposar | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Aug 1, 1996 | Jan 31, 2024 | No Longer Used |
| 68001-0265-25 | 68001-0265 | Etoposide | Etoposide | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Nov 14, 2013 | In Use | |
| 55390-0291-01 | 55390-0291 | Etoposide | Etoposide | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | May 1, 1996 | Jun 30, 2013 | No Longer Used | |
| 68001-0265-24 | 68001-0265 | Etoposide | Etoposide | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Nov 14, 2013 | In Use | |
| 44567-0507-01 | 44567-0507 | Teniposide | Teniposide | 10.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Apr 30, 2013 | In Use | |
| 16729-0262-31 | 16729-0262 | Etoposide | Etoposide | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Aug 22, 2013 | Oct 31, 2021 | No Longer Used |
| 55390-0493-01 | 55390-0493 | Etoposide | Etoposide | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Sep 28, 2001 | May 31, 2013 | No Longer Used | |
| 16729-0114-08 | 16729-0114 | Etoposide | Etoposide | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Mar 3, 2015 | In Use | |
| 70020-1910-01 | 70020-1910 | Ixabepilone | Ixempra | Chemotherapy | Antitumor Antibiotic | Epothilones | Intravenous | Oct 16, 2007 | In Use | ||
| 70020-1911-01 | 70020-1911 | Ixabepilone | Ixempra | Chemotherapy | Antitumor Antibiotic | Epothilones | Intravenous | Oct 16, 2007 | In Use | ||
| 00015-1911-13 | 00015-1911 | Ixabepilone | Ixempra | Chemotherapy | Antitumor Antibiotic | Epothilones | Intravenous | Oct 16, 2007 | Oct 31, 2017 | No Longer Used | |
| 00015-1910-12 | 00015-1910 | Ixabepilone | Ixempra | Chemotherapy | Antitumor Antibiotic | Epothilones | Intravenous | Oct 16, 2007 | Oct 31, 2017 | No Longer Used | |
| 72187-0102-03 | 72187-0102 | Elacestrant | ORSERDU | 345.0 mg/1 | Hormonal Therapy | Estrogen Receptor Antagonist | ERα | Oral | Jan 27, 2023 | In Use | |
| 72187-0101-03 | 72187-0101 | Elacestrant | ORSERDU | 86.0 mg/1 | Hormonal Therapy | Estrogen Receptor Antagonist | ERα | Oral | Jan 27, 2023 | In Use | |
| 00002-1717-56 | 00002-1717 | Imlunestrant | Inluriyo | 200.0 mg/1 | Hormonal Therapy | Estrogen Receptor Antagonist | ER⍺ | Oral | Sep 25, 2025 | In Use | |
| 00002-1717-28 | 00002-1717 | Imlunestrant | Inluriyo | 200.0 mg/1 | Hormonal Therapy | Estrogen Receptor Antagonist | ER⍺ | Oral | Sep 25, 2025 | In Use | |
| 72607-0100-00 | 72607-0100 | tazemetostat | TAZVERIK | 200.0 mg/1 | Chemotherapy | Enzyme Inhibitor | EZH2 | Oral | Jan 23, 2020 | In Use | |
| 72730-0101-01 | 72730-0101 | infigratinib | TRUSELTIQ | 125.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR | Oral | May 28, 2021 | In Use | |
| 72730-0111-01 | 72730-0111 | infigratinib | TRUSELTIQ | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR | Oral | May 28, 2021 | In Use | |
| 64842-0120-06 | 64842-0120 | FUTIBATINIB | LYTGOBI | 4.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR | Oral | Feb 3, 2023 | In Use | |
| 72730-0506-01 | 72730-0506 | infigratinib | TRUSELTIQ | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR | Oral | May 28, 2021 | In Use | |
| 64842-0120-05 | 64842-0120 | FUTIBATINIB | LYTGOBI | 4.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR | Oral | Feb 3, 2023 | In Use | |
| 64842-0120-04 | 64842-0120 | FUTIBATINIB | LYTGOBI | 4.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR | Oral | Feb 3, 2023 | In Use | |
| 72730-0202-01 | 72730-0202 | infigratinib | TRUSELTIQ | 75.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR | Oral | May 28, 2021 | In Use | |
| 50881-0027-01 | 50881-0027 | Pemigatinib | PEMAZYRE | 9.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR1, FGFR2, FGFR3 | Oral | Apr 17, 2020 | In Use |
Found 12159 results — Export these results
Home